News
GBT
32.33
+8.33%
2.49
GBT begins phase 2/3 clinical trial of GBT601 to treat sickle cell disease
Global Blood Therapeutics (NASDAQ:GBT) <a href="ht...
Seekingalpha · 5h ago
Global Blood Therapeutics Starts Phase 2 Trial of Sickle Cell Disease Drug
MT Newswires · 9h ago
Looking Into Global Blood Therapeutics's Return On Capital Employed
According to Benzinga Pro data, during Q1, Global Blood Therapeutics (NASDAQ:GBT) posted sales of $55.16 million. Earnings were up 7.03%, but Global Blood Therapeutics still reported an overall loss of $81.42 million.
Benzinga · 1d ago
JPMorgan Lowers Global Blood Therapeutics' Price Target to $36 From $39, Maintains Neutral Rating
MT Newswires · 1d ago
Biotech ETFs look to continue recent rally
Biotechnology exchange traded funds look to build upon their winning streak on Friday as investors observed a double-digit performance jump across a handful of popular funds over the past week.
Seekingalpha · 5d ago
NFL Running Back Tevin Coleman and Family Team Up with GBT to Share Playbook for Families Affected by Sickle Cell Disease
Parents of 4-year-old daughter with sickle cell disease kick off education campaign around World Sickle Cell Day and Father’s DaySOUTH SAN FRANCISCO, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announ...
GlobeNewswire · 06/16 12:00
New GBT Multinational Survey Shines a Needed Light on the Misunderstood Realities, Unseen Burden and Care Challenges of Sickle Cell Disease
Sickle Cell Health Awareness, Perspectives and Experiences (SHAPE) survey developed with international steering committee of medical experts and patient advocatesSOUTH SAN FRANCISCO, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc....
GlobeNewswire · 06/13 12:00
Wedbush Lifts Price Target on Global Blood Therapeutics to $74 From $73 on Oxbryta Estimates, Keeps Outperform Rating
MT Newswires · 06/13 06:58
How Global Blood Therapeutics Thinks It Can Take On Crispr's Gene Editing
GBT said Friday its sickle cell treatment, Oxbryta, helped lower markers of the disorder in a real-world study, but GBT stock yo-yoed.
Investor's Business Daily · 06/10 20:06
BRIEF-GBT Presents Positive New Real-World Evidence Data Further Supporting Clinical Use Of Oxbryta In Sickle Cell Disease
reuters.com · 06/10 07:09
GBT Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta® (voxelotor) in Sickle Cell Disease
Positive results from Phase 1 study of GBT601, including incremental new data, support advancing into planned Phase 2/3 trial by mid-year GBT to hold investor conference call and webcast today at 3:00 p.m. CEST (9:00 a.m. EDT) to highlight EHA data and pro...
GlobeNewswire · 06/10 07:00
Why Is CRISPR Therapeutics AG (CRSP) Up 45.9% Since Last Earnings Report?
CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 06/08 15:30
Global Blood's (GBT) Candidates for SCD Get Two FDA Tags
The FDA bestows both orphan drug and rare pediatric disease designations to Global Blood's (GBT) inclacumab and GBT021601 (GBT601) for the treatment of sickle cell disease.
Zacks · 06/07 15:23
The GBT Foundation Opens 2022 ACCEL Grant Program to Provide Up to $500,000 in Support to Sickle Cell Disease Nonprofit Healthcare Organizations and Institutions
Grant proposals accepted through July 29, 2022SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- The GBT Foundation, a 501(c)(3) organization primarily funded by Global Blood Therapeutics, Inc. (GBT), today announced that it is accepting propos...
GlobeNewswire · 06/06 14:00
BRIEF-Global Blood Therapeutics Says Gbt601 Is Expected To Advance Into Phase 2 Portion Of A Phase 2/3 Trial By Mid-Year
reuters.com · 06/06 13:16
Global Blood Therapeutics nabs FDA designations for sickle cell disease therapy
Commercial-stage biotech Global Blood Therapeutics (NASDAQ:GBT) announced on Monday that the FDA granted both orphan drug and rare pediatric disease designations for inclacumab and GBT021601 (GBT601) for the treatment of
Seekingalpha · 06/06 12:42
GBT's Inclacumab And GBT601 Receive US FDA Orphan Drug And Rare Pediatric Disease Designations For Treatment Of Sickle Cell Disease
Inclacumab is a novel P-selectin inhibitor currently in Phase 3 clinical trials to reduce vaso-occlusive crises (VOCs) and readmissions due to VOCs in patients with sickle cell disease   GBT601 is a next generation
Benzinga · 06/06 12:08
GBT’s Inclacumab and GBT601 Receive U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for the Treatment of Sickle Cell Disease
Inclacumab is a novel P-selectin inhibitor currently in Phase 3 clinical trials to reduce vaso-occlusive crises (VOCs) and readmissions due to VOCs in patients with sickle cell disease GBT601 is a next generation sickle hemoglobin (HbS) polymerization inhi...
GlobeNewswire · 06/06 12:00
Global Blood Therapeutics Receives FDA Orphan Drug, Rare Pediatric Disease Status for Sickle Cell Treatments
MT Newswires · 06/06 10:11
Global Blood (GBT) Down 15.5% Since Last Earnings Report: Can It Rebound?
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 06/03 15:32
More
Webull provides a variety of real-time GBT stock news. You can receive the latest news about Global Blood through multiple platforms. This information may help you make smarter investment decisions.
About GBT
Global Blood Therapeutics, Inc. is a biopharmaceutical company that discovers, develops and delivers treatments. The Company is focused on Oxbryta (voxelotor), which is the Food and Drug Administration (FDA) approved medicine that inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in sickle cell disease (SCD). It is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase III development to address pain crises associated with the disease, and GBT021601 (GBT601), the Company’s next-generation HbS polymerization inhibitor. The Company is focused on areas of the United States, Europe, the Gulf Cooperation Council (GCC), region of the Middle East, and Latin America.